Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page: https://medlineplus.gov/genetics/gene/ewsr1/

EWSR1 gene

EWS RNA binding protein 1

Normal Function

The EWSR1 gene provides instructions for making the EWS protein, whose function is not completely understood. The EWS protein has two regions that contribute to its function. One region, the transcriptional activation domain, allows the EWS protein to turn on (activate) the first step in the production of proteins from genes (transcription). The other region, the RNA-binding domain, allows the EWS protein to attach (bind) to the genetic blueprint for proteins called RNA. The EWS protein may be involved in piecing together this blueprint. Some studies suggest that the RNA-binding domain is able to block (inhibit) the activity of the transcriptional activation domain, and thus regulate the function of the EWS protein.

Health Conditions Related to Genetic Changes

Ewing sarcoma

Mutations involving the EWSR1 gene can cause a type of cancerous tumor known as Ewing sarcoma. These tumors develop in bones or soft tissues, such as nerves and cartilage. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor, and Askin tumor. The mutations that cause these tumors are acquired during a person's lifetime and are present only in the tumor cells. This type of genetic change, called a somatic mutation, is not inherited. The most common mutation that causes Ewing sarcoma is a rearrangement (translocation) of genetic material between chromosome 22 and chromosome 11. This translocation, written as t(11;22), fuses part of the EWSR1 gene on chromosome 22 with part of another gene on chromosome 11 called FLI1, creating an EWSR1/FLI1 fusion gene.

The protein produced from the EWSR1/FLI1 fusion gene, called EWS/FLI, has functions of the protein products of both genes. The FLI protein, produced from the FLI1 gene, attaches to DNA and regulates transcription. This protein controls the growth and development of some cell types. The EWS/FLI protein has the DNA-binding function of the FLI protein as well as the transcription regulation function of the EWS protein. It is thought that the EWS/FLI protein turns the transcription of a variety of genes on and off abnormally. This dysregulation of transcription leads to uncontrolled growth and division (proliferation) and abnormal maturation and survival of cells, causing tumor development.

The EWSR1/FLI1 fusion gene occurs in approximately 85 percent of Ewing sarcomas. Translocations that fuse the EWSR1 gene with other genes that are related to the FLI1 gene can also cause these types of tumors, although these alternative translocations are relatively uncommon. The fusion proteins produced from the less common translocations have the same function as the EWS/FLI protein.

More About This Health Condition

Other cancers

Translocations involving the EWSR1 gene are involved in many types of soft tissue sarcoma, which are cancers that cause tumors in soft tissues such as fat, muscles, and nerves. These translocations fuse the EWSR1 gene with one of several other genes. These other genes, sometimes referred to as fusion partners, seem to determine the type of tumor that develops.

The EWSR1/WT1 fusion gene causes desmoplastic small round cell tumor, a type of soft tissue sarcoma that often occurs in the abdomen. The EWSR1/ATF1 fusion gene is involved in a rare type of cancer called soft tissue clear cell sarcoma (or malignant melanoma of soft parts). In this type of cancer, tumors usually develop in the tendons, especially in the knees, feet, and ankles. A translocation that creates the EWSR1/NR4A3 fusion gene causes extraskeletal myxoid chondrosarcoma, which is a rare type of soft tissue tumor that usually occurs in the lower body, such as the thighs or buttocks. The EWSR1/DDIT3 fusion gene is sometimes found in myxoid liposarcomas, although it is an uncommon cause of this type of cancer. Myxoid liposarcomas occur in fatty tissue in many parts of the body.

Other Names for This Gene

  • Ewing sarcoma breakpoint region 1
  • Ewings sarcoma EWS-Fli1 (type 1) oncogene
  • EWS
  • EWS RNA-binding protein 1
  • EWS_HUMAN
  • RNA-binding protein EWS

Additional Information & Resources

Tests Listed in the Genetic Testing Registry

Scientific Articles on PubMed

Catalog of Genes and Diseases from OMIM

Gene and Variant Databases

References

  • Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol. 1998 Mar;18(3):1489-97. doi: 10.1128/MCB.18.3.1489. Citation on PubMed or Free article on PubMed Central
  • Li KK, Lee KA. Transcriptional activation by the Ewing's sarcoma (EWS) oncogene can be cis-repressed by the EWS RNA-binding domain. J Biol Chem. 2000 Jul 28;275(30):23053-8. doi: 10.1074/jbc.M002961200. Citation on PubMed
  • May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, Zucman J, Thomas G, Denny CT. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5752-6. doi: 10.1073/pnas.90.12.5752. Citation on PubMed or Free article on PubMed Central
  • Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 1993 Dec 15;53(24):5859-63. Citation on PubMed
  • Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials. 2009 Jan;4(1):12-26. doi: 10.2174/157488709787047585. Citation on PubMed
  • Rossow KL, Janknecht R. The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res. 2001 Mar 15;61(6):2690-5. Citation on PubMed

The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.